Pharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves

Basit Öğe Kaydı
dc.contributor.authorCorum, Orhan
dc.contributor.authorYildiz, Ramazan
dc.contributor.authorIder, Merve
dc.contributor.authorAltan, Feray
dc.contributor.authorOk, Mahmut
dc.contributor.authorUney, Kamil
dc.date.accessioned2024-04-24T17:11:47Z
dc.date.available2024-04-24T17:11:47Z
dc.date.issued2019
dc.departmentDicle Üniversitesien_US
dc.description.abstractThe aim of this study was to evaluate the pharmacokinetics and bioavailability of cefquinome (CFQ) and ceftriaxone (CTX) following intravenous (IV) and intramuscular (IM) administrations in premature calves. Using a parallel design, 24 premature calves were randomly divided into the two antibiotic groups. Each of the six animals in the first group received CFQ (2 mg/kg) through IV or IM administration. The second group received CTX (20 mg/kg) via the same administration route. Plasma concentrations of the drugs were analyzed by high-performance liquid chromatography and noncompartmental methods. Mean pharmacokinetic parameters of CFQ and CTX following IV administration were as follows: elimination half-life (t(1/2 lambda z)) 1.85 and 3.31 hr, area under the plasma concentration-time curve (AUC(0-infinity)) 15.74 and 174 hr * mu g/ml, volume of distribution at steady-state 0.37 and 0.45 L/kg, and total body clearance 0.13 and 0.12 L hr(-1) kg(-1), respectively. Mean pharmacokinetic parameters of CFQ and CTX after IM injection were as follows: peak concentration 4.56 and 25.04 mu g/ml, time to reach peak concentration 1 and 1.5 hr, t(1/2 lambda z) 4.74 and 3.62 hr, and AUC(0-infinity) 22.75 and 147 hr * mu g/ml, respectively. The bioavailability of CFQ and CTX after IM injection was 141% and 79%, respectively. IM administration of CFQ (2 mg/kg) and CTX (20 mg/kg) can be recommended at 12-hr interval for treating infections caused by susceptible bacteria, with minimum inhibitory concentration values of <= 0.5 and <= 4 mu g/ml, respectively, in premature calves. However, further research is indicated to assess the pharmacokinetic parameters following multiple doses of the drug in premature calves.en_US
dc.identifier.doi10.1111/jvp.12789
dc.identifier.endpage639en_US
dc.identifier.issn0140-7783
dc.identifier.issn1365-2885
dc.identifier.issue6en_US
dc.identifier.pmid31197850
dc.identifier.scopus2-s2.0-85067614931
dc.identifier.scopusqualityQ1
dc.identifier.startpage632en_US
dc.identifier.urihttps://doi.org/10.1111/jvp.12789
dc.identifier.urihttps://hdl.handle.net/11468/17719
dc.identifier.volume42en_US
dc.identifier.wosWOS:000501034000008
dc.identifier.wosqualityQ2
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoenen_US
dc.publisherWileyen_US
dc.relation.ispartofJournal of Veterinary Pharmacology and Therapeutics
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectBioavailabilityen_US
dc.subjectCefquinomeen_US
dc.subjectCeftriaxoneen_US
dc.subjectPharmacokineticsen_US
dc.subjectPremature Calvesen_US
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calvesen_US
dc.titlePharmacokinetics and bioavailability of cefquinome and ceftriaxone in premature calves
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu